Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

r value of warrant liability

-- Deemed dividend

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense - Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items - Non-GAAP net loss and diluted net loss per common share

exclude other unusual or non-recurring items that are evaluated on an

individual basis. Amicus' evaluation of whether to exclude an item for

purposes of determining its non-GAAP financial measures considers both

the quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to its ongoing business operations, and (iii) whether or not Amicus

expects it to occur as part of its normal business on a regular basis.

Items excluded for purposes of determining non-GAAP net loss and

diluted net loss per common sh
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, ... leadership gift of $100 million from The Marie-Josée ... a new laboratory building that will be the ... The Marie-Josée and Henry R. Kravis Research Building, ... FDR Drive, spanning approximately three city blocks following ...
(Date:5/20/2015)... , May 20, 2015  Cypher Genomics, ... a collaboration with Celgene Corporation to apply Cypher,s ... biomarkers that associate with patient response to innovative ... intended to help accelerate patient access to the ... in clinical research and development and potentially inform ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... CHICAGO, Sept. 3 The Female Health Company (Nasdaq: ... Female Condom® , today announced that the Company,s CEO, O.B. ... a presentation at Rodman & Renshaw,s Global Investment Conference ... the Hubbard Salon, 5th floor. The Conference will ...
... -- DALLAS, Texas, September 3, 2010 ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Researchers at the Georgia Institute of Technology have developed ... current is switched by an electric field generated by ... The devices, which include transistors and diodes, could ... systems (MEMS) and microfluidic devices. The mechanical action ...
Cached Biology Technology:The Female Health Company to Present at Rodman & Renshaw's Annual Global Investment Conference on Wednesday, September 15, 2010 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 4New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 5New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 6New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 7New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 8Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 2Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 3Researchers create new class of piezoelectric logic devices using zinc oxide nanowires 4
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... experiments with mice, a team of scientists from the United ... dose of one protein is sufficient to change the normal ... doubling the risk that a cancer-causing genetic mutation will trigger ... double protein dose as well. , In the Feb. 24 ...
... broadens our insight into,the cause of certain kinds ... Center (Rotterdam, The Netherlands) have,employed an evolutionarily ancient ... damage responsible for the onset of skin-tumor,development. The ... be useful in developing preventative therapies against skin,cancer. ...
... study published in the journal Blood, Yale scientists identify the ... to clonally expand into large populations of malignant lymphocytes. , ... the white blood cells of the immune system. Finding CTCL ... Edelson, M.D., Director of the Yale Cancer Center, and professor ...
Cached Biology News:It's not all genetic: Common epigenetic problem doubles cancer risk in mice 2It's not all genetic: Common epigenetic problem doubles cancer risk in mice 3Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer 2Source of molecular triggers in cutaneous T cell lymphoma identified 2
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
albumin from bovine serum (BSA), Texas Red® conjugate...
Biology Products: